Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition

被引：27
|
作者：
Hude, Ida [1 ,2 ]
Sasse, Stephanie [1 ]
Broeckelmann, Paul J. [1 ]
von Tresckow, Bastian [1 ]
Momotow, Jesko [1 ]
Engert, Andreas [1 ]
Borchmann, Sven [1 ]
机构：
[1] Univ Hosp Cologne, GHSG, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Ctr Zagreb, Div Haematol, Dept Internal Med, Zagreb, Croatia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷 / 06期
关键词：
Hodgkin lymphoma; immune checkpoint inhibition; biomarkers; eosinophils; immunotherapy; BRENTUXIMAB VEDOTIN; NIVOLUMAB; BLOCKADE; FAILURE;
D O I：
10.1111/bjh.14705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：837 / 840
页数：4
相关论文
共 50 条
  • [31] Dominant negative PD1 armored CART cells to induce remission in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.
    Pu, Chengfei
    Huang, Liansheng
    Su, Yang
    Ding, Tianling
    Xiao, Xibin
    Jin, Lina
    Cao, Zhiyuan
    Wu, Ting
    Chen, Tong
    Ding, Luying
    Zhang, Xiaohong
    Lan, Haifeng
    Wu, Zhao
    Xiao, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] PD-1 Inhibitors May Restore Chemo-sensitivity in Relapsed/Refractory Classical Hodgkin Lymphoma
    Calabretta, Eleonora
    Ricci, Francesca
    Morello, Lucia
    Magagnoli, Massimo
    Santoro, Armando
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S308 - S308
  • [33] PROGRESSION-FREE SURVIVAL IN ADVANCED CLASSICAL HODGKIN LYMPHOMA PATIENTS WITH BULKY DISEASE AFTER ABVD WITHOUT RADIATION THERAPY IN ERA PET
    Puccini, B.
    Rigacci, L.
    Romano, I.
    Berti, V.
    Palazzo, M.
    Galli, E.
    Ciolli, G.
    Merlini, M.
    Vannucchi-, A. M.
    Nassi, L.
    HAEMATOLOGICA, 2021, 106 (10) : 138 - 139
  • [34] Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.
    Derosa, Lisa
    Routy, Bertrand
    Mezquita, Laura
    Naltet, Charles
    Enot, David
    Fidelle, Marine
    Goubet, Anne-Gaelle
    Soria, Jean-Charles
    Massard, Christophe
    Goldwasser, Francois
    Zitvogel, Laurence
    Brosseau, Solenn
    Escudier, Bernard J.
    Loriot, Yohann
    Zalcman, Gerard
    Besse, Benjamin
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
    Shi, Yuankai
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Xiong, Yan
    Zhou, Hui
    Du, Xinhua
    Wang, Xiong
    Peng, Bo
    EBIOMEDICINE, 2020, 54
  • [36] Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents
    Shah, Harsh
    Jang, Hyejeong
    Singh, Paramveer
    Kosti, Jorgena
    Kin, Andrew
    Alavi, Asif
    Ratanatharathorn, Voravit
    Ayash, Lois
    Uberti, Joseph
    Ramchandren, Radhakrishnan
    Kim, Seongho
    Deol, Abhinav
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 813 - 820
  • [37] Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US
    Desai, Kaushal D.
    Yang, Xiaoqin
    Gilligan, Adrienne M.
    Li, Yeran
    Raut, Monika
    Nahar, Akash
    BLOOD, 2020, 136
  • [38] Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
    McClune, Brian L.
    Ahn, Kwang Woo
    Wang, Hai-Lin
    Antin, Joseph H.
    Artz, Andrew S.
    Cahn, Jean-Yves
    Deol, Abhinav
    Freytes, Cesar O.
    Hamadani, Mehdi
    Holmberg, Leona A.
    Jagasia, Madan H.
    Jakubowski, Ann A.
    Kharfan-Dabaja, Mohamed A.
    Lazarus, Hillard M.
    Miller, Alan M.
    Olsson, Richard
    Pedersen, Tanya L.
    Pidala, Joseph
    Pulsipher, Michael A.
    Rowe, Jacob M.
    Saber, Wael
    van Besien, Koen W.
    Waller, Edmund K.
    Aljurf, Mahmoud D.
    Akpek, Goergun
    Bacher, Ulrike
    Chao, Nelson J.
    Chen, Yi-Bin
    Cooper, Brenda W.
    Dehn, Jason
    de Lima, Marcos J.
    Hsu, Jack W.
    Lewis, Ian D.
    Marks, David I.
    McGuirk, Joseph
    Cairo, Mitchell S.
    Schouten, Harry C.
    Szer, Jeffrey
    Ramanathan, Muthalagu
    Savani, Bipin N.
    Seftel, Matthew
    Socie, Gerard
    Vij, Ravi
    Warlick, Erica D.
    Weisdorf, Daniel J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (07) : 960 - 968
  • [39] Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Beynarovich, Anastasiya V.
    Lepik, Kirill
    Mikhailova, Nataliia
    Kondakova, Elena
    Zalaylov, Yuri
    Borzenkova, Evgeniya
    Babenko, Elena
    Darskaya, Elena I.
    Moiseev, Ivan S.
    Zander, Axel
    Afanasyev, Boris
    BLOOD, 2019, 134
  • [40] Inferior progression-free survival after autotransplant for relapsed or refractory aggressive non-hodgkin's lymphoma in patients > 60 versus < 60 years of age.
    Kuruvilla, John
    Gupta, Vikas
    Zaretsky, Yael
    Zadeh, Sahar
    Nagy, Tracy
    Keating, Armand
    Crump, Michael
    BLOOD, 2006, 108 (11) : 874A - 874A
12345